目的 觀察拓?fù)涮婵德?lián)合多西他賽治療小細(xì)胞肺癌的臨床療效，并評價其有效性和安全性。方法 將2010年1月-2013年1月來高唐縣人民醫(yī)院就診的小細(xì)胞肺癌患者100例，隨機(jī)分為治療組和對照組，各50例。對照組iv多西他賽注射液75 mg/（m²·d），治療組在對照組的基礎(chǔ)上注射用鹽酸拓?fù)涮婵?.5 mg/（m²·d）；3周為一個周期，至少治療4周期。治療結(jié)束后，比較兩組的臨床療效和不良反應(yīng)。結(jié)果 治療組和對照組的部分緩解率分別為36.0%、28.0%，疾病控制率分別為74.0%、58.0%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療組和對照組的中位生存時間分別為10.2、7.3個月，中位無進(jìn)展生存時間分別為3.2、2.1個月，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療過程中兩組患者均可發(fā)生惡心、嘔吐、腹瀉、食欲不振、肝功能損害、腎功能損害、咳嗽、發(fā)熱、皮疹、痤瘡、白細(xì)胞減少、血小板減少、血紅蛋白降低等不良反應(yīng)。治療組患者消化系統(tǒng)和血液系統(tǒng)的不良反應(yīng)比較大，28.0%出現(xiàn)惡心，24.0%發(fā)生白細(xì)胞減少，28.0%血小板減少，與對照組比較差異有統(tǒng)計學(xué)意義（P<0.05）。其他不良反應(yīng)與對照組比較沒有統(tǒng)計學(xué)意義。結(jié)論 拓?fù)涮婵德?lián)合多西他賽治療小細(xì)胞肺癌的療效顯著，安全有效，值得臨床借鑒。

Objective To observe the clinical efficacy of topotecan combined with docetaxel in treatment of small cell lung cancer and to evaluate the efficacy and safety for clinic. Methods The patients (100 cases) with small cell lung cancer who came to Gaotang County People's Hospital from January 2010 to January 2013 were randomly divided into treatment and control groups, 50 cases in each group. The patients in the control group were treated with 75 mg/(m²·d) Docetaxel for Injection. On the basis of control group, the patients in the treatment group were given 1.5 mg/(m²·d) Topotecan Hydrochloride for Injection. One course was 3 weeks, and all patients accepted administration for at least four courses. The clinical efficacy and side effects of two groups were compared. Results The RR rates in the treatment and control groups were 36.0% and 28.0%; The DCR rates were 74.0% and 58.0%, with significant difference between two groups (P < 0.05). The median OS time was 10.2 and 7.3 months; The median PFS time was 3.2 and 2.1 months, with significant difference (P < 0.05). The patients in both groups had side effects such as nausea, vomiting, diarrhea, inappetence, abnormal liver function, abnormal renal function, cough, fever, rash, acne, reduced leukocyte, hemoglobin, and blood platelet. The patients in the treatment group had more serious adverse reactions in digestive and blood systems. Nausea (28.0%), reduced leukocyte (24.0%), and reduced blood platelet (28.0%) were higher than those in the control group with significant difference (P < 0.05). The remaining aspects adverse reactions in patients showed no significant difference between two groups. Conclusion Topotecan combined with docetaxel in the treatment of small cell lung cancer has good effect, and it is a safe and effective manner worthy of reference.

國家自然科學(xué)基金資助項目（30971307）